✦ LIBER ✦

Activity of the oral MEK inhibitor trametinib in patients with advanced melanoma: a phase 1 dose-escalation trial

✍ Scribed by Gerald S Falchook; Karl D Lewis; Jeffrey R Infante; Michael S Gordon; Nicholas J Vogelzang; Douglas J DeMarini; Peng Sun; Christopher Moy; Stephen A Szabo; Lori T Roadcap; Vijay GR Peddareddigari; Peter F Lebowitz; Ngocdiep T Le; Howard A Burris III; Wells A Messersmith; Peter J O'Dwyer; Kevin B Kim; Keith Flaherty; Johanna C Bendell; Rene Gonzalez; Razelle Kurzrock; Leslie A Fecher

Book ID: 119608931
Publisher: The Lancet
Year: 2012
Tongue: English
Weight: 225 KB
Volume: 13
Category: Article
ISSN: 1470-2045
DOI: 10.1016/s1470-2045(12)70269-3

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Safety, pharmacokinetic, pharmacodynamic

Safety, pharmacokinetic, pharmacodynamic, and efficacy data for the oral MEK inhibitor trametinib: a phase 1 dose-escalation trial

✍ Jeffrey R Infante; Leslie A Fecher; Gerald S Falchook; Sujatha Nallapareddy; Mic 📂 Article 📅 2012 🏛 The Lancet 🌐 English ⚖ 246 KB

608 Phase I Dose-escalation Trial of a S

608 Phase I Dose-escalation Trial of a Selective Oral MEK1/2 Inhibitor, Pimasertib (MSC1936369B), Combined with an mTOR Inhibitor, Temsirolimus, in Patients with Advanced Solid Tumors

✍ Naing, A.; Mita, M.; Komarnitsky, P.; Milner, A.; von Richter, O.; Ogden, J.; Pi 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 64 KB

A phase 1b study of trametinib, an oral

A phase 1b study of trametinib, an oral Mitogen-activated protein kinase kinase (MEK) inhibitor, in combination with gemcitabine in advanced solid tumours

✍ Infante, Jeffrey R.; Papadopoulos, Kyriakos P.; Bendell, Johanna C.; Patnaik, Am 📂 Article 📅 2013 🏛 Elsevier Science 🌐 English ⚖ 448 KB

Phase Ib/II, open-label, dose-escalation

Phase Ib/II, open-label, dose-escalation study of LGX818, an oral selective BRAF inhibitor, in combination with MEK162, an oral MEK1/2 inhibitor, in patients with BRAF V600-dependent advanced solid tumors: preliminary results

✍ Kefford, Richard; Sullivan, Ryan J; Miller, Wilson H; Elez, Elena M; Tan, Daniel 📂 Article 📅 2014 🏛 BioMed Central 🌐 English ⚖ 91 KB

368 A multi-center Phase 1, dose-escalat

368 A multi-center Phase 1, dose-escalation trial to determine the safety and pharmacokinetics/pharmacodynamics of BAY 86-9766 (RDEA119), a MEK inhibitor, in advanced cancer patients

✍ C. Weekes; D.D. Von Hoff; A.A. Adjei; L. Yeh; D. Leffingwell; B. Sheedy; C. Iver 📂 Article 📅 2010 🏛 Elsevier Science 🌐 English ⚖ 45 KB

Dabrafenib in patients with melanoma, un

Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a phase 1 dose-escalation trial

✍ Gerald S Falchook; Georgina V Long; Razelle Kurzrock; Kevin B Kim; Tobias H Arke 📂 Article 📅 2012 🏛 The Lancet 🌐 English ⚖ 576 KB